CN117025639A - 一种phlI基因及其在提高2,4-二乙酰基间苯三酚产量中的应用 - Google Patents
一种phlI基因及其在提高2,4-二乙酰基间苯三酚产量中的应用 Download PDFInfo
- Publication number
- CN117025639A CN117025639A CN202311170521.7A CN202311170521A CN117025639A CN 117025639 A CN117025639 A CN 117025639A CN 202311170521 A CN202311170521 A CN 202311170521A CN 117025639 A CN117025639 A CN 117025639A
- Authority
- CN
- China
- Prior art keywords
- phli
- gene
- dapg
- strain
- yield
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PIFFQYJYNWXNGE-UHFFFAOYSA-N 2,4-diacetylphloroglucinol Chemical compound CC(=O)C1=C(O)C=C(O)C(C(C)=O)=C1O PIFFQYJYNWXNGE-UHFFFAOYSA-N 0.000 title claims abstract description 126
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 51
- 239000013612 plasmid Substances 0.000 claims abstract description 25
- 238000010353 genetic engineering Methods 0.000 claims abstract description 10
- 108091008053 gene clusters Proteins 0.000 claims abstract description 6
- 241000894006 Bacteria Species 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 230000002018 overexpression Effects 0.000 claims description 11
- 241000589516 Pseudomonas Species 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 230000001502 supplementing effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 description 17
- 238000001514 detection method Methods 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- YOQHLDOEJYEQRA-UHFFFAOYSA-N 1-(3,5-diacetyl-2,4,6-trihydroxyphenyl)ethanone Chemical compound CC(=O)C1=C(O)C(C(C)=O)=C(O)C(C(C)=O)=C1O YOQHLDOEJYEQRA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 240000000220 Panda oleosa Species 0.000 description 2
- 235000016496 Panda oleosa Nutrition 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 101150068097 phlG gene Proteins 0.000 description 2
- 244000000003 plant pathogen Species 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100039239 Amidophosphoribosyltransferase Human genes 0.000 description 1
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
- 238000003512 Claisen condensation reaction Methods 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 101100243369 Escherichia coli pemI gene Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 108010030975 Polyketide Synthases Proteins 0.000 description 1
- 241001602248 Pseudomonas fluorescens F113 Species 0.000 description 1
- 241000918585 Pythium aphanidermatum Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100406769 Serratia liquefaciens phlA gene Proteins 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010060641 flavanone synthetase Proteins 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- LTYOQGRJFJAKNA-VFLPNFFSSA-N malonyl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-VFLPNFFSSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 101150001698 phlD gene Proteins 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 101150025220 sacB gene Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
- C12P7/26—Ketones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/38—Pseudomonas
- C12R2001/39—Pseudomonas fluorescens
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种phlI基因及其在提高2,4‑二乙酰基间苯三酚产量中的应用,涉及基因工程技术领域,所述phlI基因正调控2,4‑DAPG合成,该基因具有如SEQ ID NO.1所示的核苷酸序列,所述phlI基因过表达或敲除后回补提高2,4‑二乙酰基间苯三酚产量。本发明通过在敲除菌株ΔphlI和野生菌株2P24中导入pBBR5‑phlI质粒,回补和过表达phlI基因,验证2,4‑DAPG基因簇上基因phlI的功能,获得2,4‑DAPG产量的提升。
Description
技术领域
本发明涉及基因工程技术领域,涉及一种phlI基因及其在提高2,4-二乙酰基间苯三酚产量中的应用。
背景技术
荧光假单胞菌(Pseudomonas fluorescens)是典型的植物有益菌,其不仅分布广,数量丰,营养需要简单,繁殖快,竞争定殖力强,而且在许多植物病原体的生物控制中发挥着重要作用,例如,棉花猝倒病,小麦全蚀病和烟草黑根腐烂。
荧光假单胞菌在根系定殖过程中,可产生大量铁载体、多种抗生素和活性物质,引起宿主植物的诱导植物系统抗性(ISR)或特异性干扰真菌致病因子从而保护植物免受病原体危害,其中抗生素2,4-DAPG(2,4-二乙酰基间苯三酚)受到广泛关注。2,4-DAPG具有广谱抗病毒、抗细菌、抗真菌、抗寄生虫的特性,可以抑制多种植物病原体,包括真菌、蠕虫和线虫,并负责许多荧光假单胞菌的生物防治能力,同时2,4-DAPG是ISR的因素之一,会使植物产生对病原体的抗性,从而增强植物保护,并促进植物根系中氨基酸的分泌。2,4-DAPG有助于抑制小麦全蚀病、番茄黑根病和小麦根腐病等多种植物疾害,故作为一种广谱抗生素在生物防治领域具备广泛的应用前景。
目前确定的参与2,4-DAPG的生物合成、调控、输出和降解的基因簇由8个基因phlAC BDEFGH组成,其中phlACBD位于一个操纵子上,phlD基因编码III型聚酮合成酶(PKS)催化起始底物(通常为酰基辅酶A)与多个延长剂底物单元(通常为丙二酰辅酶A)的反复缩合、脱羧、克莱森缩合环化形成间苯三酚。PhlA、PhlC和PhlB单元组成的多聚体酶称为MAPG乙酰转移酶(MAPG ATase),可以在不使用辅酶A激活的底物的情况下催化C-C键的形成。假单胞菌属中DAPG的产生受TetR家族的两个翻译抑制因子PhlF和PhlH的调控。PhlF作为二聚体与位于phlA转录起始位点下游的反向重复序列(phO)结合,从而抑制phlACBD的表达,当phlF基因敲除后突变菌株产生2,4-DAPG的水平比野生型提高了三倍。PhlH结合到phlG的上游序列,并抑制其表达,阻止phlG介导的DAPG降解,当phlH基因敲除后缺失菌株产生2,4-DAPG的水平明显降低于野生型水平,当其回补后回补菌株产生2,4-DAPG的水平与野生型相当。DAPG被锌依赖性水解酶PhlG降解,PhlG通过切割连接乙酰基和酚环的一个C-C键,将DAPG降解为MAPG和醋酸盐,这种酶对其底物DAPG具有高度特异性,因为它无法降解结构类似的化合物,如MAPG或三乙酰基间苯三酚,phlG缺失和回补后并不影响合成基因的表达。phlE基因位于phlACBD操纵子的下游,编码一个公认的渗透酶,被认为是主要的促进因子超家族的成员,有12个跨膜片段。PhlE被认为在phl输出中起作用,在P.fluorescens F113中,破坏掉phlE基因可以导致2,4-DAPG产生量的减少以及细菌本身对2,4-DAPG抗性的降低,并且通过突变体胞内外含量检测及结构模拟发现phlE基因参与2,4-DAPG的外排,而回补和过表达phlE基因后菌株所产生的2,4-DAPG含量与野生型基本一致。
PhlI是近几年新发现的假定蛋白,目前功能尚不明确。Jennifer A等人通过ST-PCR分析P.fluorescens Q2-1和Q1-87 phl簇的侧翼区域,发现Q2-1/Q1-87中phl簇3’区域phlE基因的下游存在一个921个高度保守的核苷酸序列,其一致性和相似性水平与phl簇中的基因相当,这一假定基因在P.fluorescens Q2-1、Q1-87、F113和P.protegens Pf-5菌株中都存在,这表明这种假定的基因可能构成phl基因簇的一个额外基因,以某种方式在2,4-DAPG生产中发挥作用,被命名为phlI,但是具体在2,4-DAPG合成和调控的功能仍然未知。
发明内容
本发明的目的在于,在phlI的正调控2,4-DAPG合成的基础上,提供两种基因工程菌株ΔphlI::pBBR5pemIK-phlI和2P24/pBBR5pemIK-phlI及其在提高2,4-DAPG产量中的应用。
本发明通过以下技术方案来实现上述目的:
本发明第一目的在于提供一种phlI基因,所述phlI基因正调控2,4-DAPG合成,该基因具有如SEQ ID NO.1所示的核苷酸序列。
进一步改进在于,所述phlI基因位于2,4-DAPG基因簇上。
本发明第二目的在于提供一种上述phlI基因在提高2,4-二乙酰基间苯三酚产量中的应用。
进一步改进在于,所述phlI基因过表达或敲除后回补提高2,4-二乙酰基间苯三酚产量。
本发明第三目的在于提供一种重组质粒,所述重组质粒中包含phlI启动子和上述phlI基因。
进一步改进在于,所述重组质粒中插入片段具有如SEQ ID NO.3所示的核苷酸序列,所述如SEQ ID NO.3所示的核苷酸序列包含phlI启动子序列和SEQ ID NO.1所示的所述phlI基因序列。
进一步改进在于,所述重组质粒为pBBR5pemIK质粒。
本发明第四目的在于提供高产2,4-DAPG的遗传工程菌,所述遗传工程菌包含上述重组质粒,所述遗传工程菌为在敲除菌株ΔphlI中回补phlI基因或野生菌株2P24中过表达phlI基因制备获得。
进一步改进在于,所述遗传工程菌为荧光假单胞菌Pseudomonas fluorescensΔphlI或Pseudomonas fluorescens 2P24,其中,工程菌分别为Escherichia coli DH5α或P.fluorescens 2P24。
本发明第五目的在于提供一种上述遗传工程菌在提高2,4-二乙酰基间苯三酚产量中的应用。
本发明的原理为:2,4-DAPG作为一种广谱抗生素在生物防治领域具备广泛的应用前景,更好地了解2,4-DAPG生物合成的基因调控,有助于提高2,4-DAPG的工业产量,前期研究发现一种未知功能的基因位于2,4-DAPG合成基因簇中,通过基因敲除和回补获得phlI缺失菌株、回补菌株和过表达菌株,通过菌株发酵和HPLC检测确定phlI基因正调控2,4-DAPG的合成,当phlI基因回补和过表达时相对于野生型菌株2,4-DAPG产量提高4、5倍,从而获得了高产2,4-DAPG的工程菌株,具备较高的应用价值。
本发明具有如下有益效果:
通过生物信息学和发酵数据确定未知功能基因phlI参与2,4-DAPG合成,且正调控2,4-DAPG的合成,通过发酵HPLC检测确定当phlI基因回补和过表达时相对于野生型菌株2,4-DAPG产量提高4、5倍。
附图说明
图1为pK18mobSacB-phlI载体示意图;
图2为pBBR5pemIK-phlI载体示意图;
图3为标准品2,4-DAPG高效液相色谱检测图;
图4为野生型2P24的2,4-DAPG高效液相色谱检测图;
图5为敲除菌株ΔphlI的2,4-DAPG高效液相色谱检测图;
图6为回补菌株ΔphlI::pBBR5pemIK-phlI的2,4-DAPG高效液相色谱检测图;
图7为回补空载菌株ΔphlI/pBBR5pemIK的2,4-DAPG高效液相色谱检测图;
图8为过表达菌株2P24/pBBR5pemIK-phlI的2,4-DAPG高效液相色谱检测图;
图9为过表达空载菌株2P24/pBBR5pemIK的2,4-DAPG高效液相色谱检测图;
图10为各菌株2,4-DAPG的最终产量对比图。
具体实施方式
下面结合附图对本申请作进一步详细描述,有必要在此指出的是,以下具体实施方式只用于对本申请进行进一步的说明,不能理解为对本申请保护范围的限制,该领域的技术人员可以根据上述申请内容对本申请作出一些非本质的改进和调整。
1、材料
本实验所用所有试剂如无特殊说明均为常规试剂,均使用去离子水配制,所使用到的仪器均为实验室常规仪器。
(1)用酶试剂购自Thermo公司,提取质粒所用的试剂盒和回收DNA片段所用的试剂盒购自诺唯赞公司,相应的操作步骤按照产品说明书进行;所有培养基如无特别说明均用去离子水配制。
(2)敲除质粒pK18mobsacB带nptII(卡那霉素抗性基因)抗性标记,及sacB选择性标记。
(3)pBBR5pemIK质粒带广谱复制子pBBR1,能在多种宿主细胞中进行自主复制,pBBR1复制子为中低拷贝复制子,携带pemI/K抗内毒素基因,能提高质粒在宿主细胞内的稳定性;带庆大霉素抗性标记。
(4)本实验使用试剂及培养基配方如下:
LB培养基:酵母粉5g,NaCl 10g,蛋白胨10g,定容至1L;
KB培养基(g/L):蛋白胨10g,甘油10ml,MgSO4·7H2O 1.5g,K2HPO4 1.5g,pH 7.0-7.2,定容至1L。
本实验各个步骤均按照标准的分子克隆技术和微生物操作进行,本实验所使用的方法如下,不受具体实施案例的影响。
2、方法
2.1构建phlI敲除质粒pK18mobsacB-phlI
以P.fluorescens2P24基因组DNA为模板,phlI基因碱基序列如SEQ ID NO.1所示,pK18mobsacB-phlI质粒插入片段的碱基序列如SEQ ID NO.2所示,通过PCR扩增获得phlI的上下游同源臂:
上游同源臂正向引物序列为:5'-CCGGAATTCGTGGTTTCCATCTGCTTCATGGTC A-3',
反向引物序列为:5'-TGCTCTAGACACTTCCCGACTTTGACCGG-3';
下游同源臂正向引物序列为:5'-TGCTCTAGAGAGCTGGTTTCGCTGGTTCCATTG C-3',
反向引物序列为:5'-CCCAAGCTTGTGTCCCTGCCTGCCACCGT-3'。
克隆所得的上游同源臂由EcoRⅠ,XbaⅠ双酶切,下游同源臂由XbaⅠ,HindⅢ双酶切,载体pK18mobSacB经EcoRⅠ,HindⅢ双酶切后,利用回收试剂盒分别回收酶切后的上下游同源臂片段和载体pK18mobSacB片段,利用连接酶将三片段进行连接,连接产物转化E.coliDH5α,筛选出阳性克隆,得到重组质粒pK18mobSacB-phlI,如图1所示,其上下游同源臂核苷酸序列如SEQ ID NO.4和SEQ ID NO.5所示。
2.2制备敲除菌株ΔphlI
将重组质粒pK18mobSacB-phlI转化到E.coliS17-1λpir的感受态细胞中,涂板到含有卡那抗性的LB固体平板在37℃进行过夜培养获得供体菌株,在28℃培养计划进行基因敲除的受体菌株——P.fluorescens2P24,调单到含有相应抗性的5mLLB液体培养基中,在37℃和28℃摇床中培养8h获得供受体菌株,低速离心收集菌体,用新鲜的无抗LB培养基清洗2-3次后用一定体积的LB培养基重新悬浮,按照供体菌:受体菌=1:1的体积比点在放在无抗LB平板的滤纸中间,正面放置28℃恒温培养箱中培养6-8h。此时,重组质粒pK18mobSacB-phlI会从供体菌株S17-1λpir接合转移到受体菌株2P24中,然后用无抗新鲜LB液体培养基将滤纸上的菌洗下来,按照一定的稀释比例对菌液进行稀释并且均匀涂布到带有双重抗生素(pK18mobSacB自身带有卡那抗性和受体菌2P24自身具备氨苄抗性)的LB固体培养基中28℃培养2d,迫使其在抗生素压力下发生第一次同源重组,菌株长起来后,挑取单克隆且通过菌液PCR的方法筛选已经将pK18mobSacB-phlI整合到基因组上的单交换菌株。
将已验证为发生单交换的受体菌株在无抗培养基中培养10h,随后按照合适的比例进行稀释,并均匀涂布与含有10%蔗糖和氨苄抗生素的固体LB平板上,在蔗糖致死压力下迫使其发生第二次同源重组,采用菌液PCR的方法来验证已经发生两次同源重组的受体菌株,从而获得缺失突变菌ΔphlI。
2.3phlI回补质粒pBBR5pemIK-phlI的构建
以P.fluorescens2P24基因组DNA为模板,通过PCR扩增克隆获得phlI启动子片段和基因片段:
phlI启动子片段正向引物序列为:5‘-CGGGGTACCCAGACCGGATAAAACACCAG C-3’
反向引物序列为:5‘-AATGGGTCATGTTCTTTCCCCTTCTTTCCC-3’
phlI基因片段正向引物序列为:5‘-GGGAAAGAACATGACCCATTATGTGATGTT-3’
反向引物序列为:5‘-CCCAAGCTTTCAGAACCTCTTAGGCACGG-3’
通过在启动子片段和基因片段的反、正向PCR引物的5’引入了双方的10bp末端同源序列,使得启动子片段和基因片段PCR产物5’和3’末端分别带有与双方末端对应的完全一致的序列,通过重叠PCR获得一个启动子+基因的完整片段,序列如SEQ ID NO.3所示。克隆所得的phlI启动子+基因片段和pBBR5pemIK载体经KpnⅠ,HindⅢ双酶切,利用胶回收试剂盒回收酶切后,进行连接,连接产物转E.coliDH5α,筛选出阳性克隆,得到重组质粒pBBR5pemIK-phlI。
2.4构建phlI回补菌株和过表达菌株
以接合转移方式将pBBR5pemIK-phlI质粒导入假单胞菌ΔphlI和2P24中,那么当大肠杆菌和假单胞菌共培养后,取共培养液梯度稀释涂双抗(庆大霉素/氨苄霉素)LA平板所获得克隆即为回补和过表达菌株。
若以电转方式将pBBR5pemIK质粒导入假单胞菌ΔphlI和2P24中,那么双抗LA平板所获得克隆即为空载菌株。获得的回补菌株记为ΔphlI::pBBR5pemIK-phlI,过表达菌株记为2P24/pBBR5pemIK-phlI。pBBR5pemIK-phlI载体示意图如图2所示。
2.5发酵实验
获得菌株之后进行发酵实验,主要涉及野生型荧光假单胞菌2P24、缺失突变菌ΔphlI、回补空载ΔphlI/pBBR5pemIK、回补菌株ΔphlI::pBBR5pemIK-phlI、过表达空载2P24/pBBR 5pemIK、过表达菌株2P24/pBBR5pemIK-phlI。
2.5.1培养菌株
在双抗(庆大霉素/氨苄霉素)平板获得回补或过表达菌株之后,挑取单克隆接种至含20mLLB培养基的50mL三角瓶中,按0.1%添加抗生素,28℃200rpm振荡培养16h;按5%接种量转接至含50mLKB培养基的250mL三角瓶中,按0.1%添加合适抗生素,依次接种野生型荧光假单胞菌2P24、缺失突变菌ΔphlI、回补空载ΔphlI/pBBR5pemIK、回补菌株ΔphlI::pBBR5pemIK-phlI、过表达空载2P24/pBBR5pemIK、过表达菌株2P24/pBBR5pem IK-phlI,28℃200rpm振荡培养。
2.5.2高效液相色谱仪测定三种菌株中2,4-DAPG含量
取24h发酵液1mL至1.5mL离心管,12000rpm离心10min之后,将上清液转移至新的1.5ml离心管,用0.22μm有机滤头过滤,转移至HPLC进样瓶内。同时各取0.2ml发酵液至酶标板,用酶标仪测定实时OD600,用于后面结果可信度的评估依据。
随后制备标品,称取10mg2,4-DAPG,溶于1mL甲醇,制备成10g/L母液;梯度稀释成50mg/L,100mg/L,500mg/L,1000mg/L。
随后用HPLC检测2,4-DAPG含量(流动相:A相为乙腈+0.1%三氟乙酸;B相为ddH2O+0.1%三氟乙酸;色谱柱:WondaSilC18-WRcolumn(5μm,4.6x150mm);检测条件:A相5%,B相95%,流速1mL/min,柱温35℃,检测波长270nm,检测时间15min/样品,2,4-DAPG保留时间为8.9min),结果如图3-9所示。
3、结果
具体效果在摇瓶水平上,如图10所示,用于对照的野生型菌株2P24的2,4-DAPG平均产量为33.284mg/L,缺失突变菌株ΔphlI的产量为9.542mg/L,回补空载ΔphlI/pBBR5pemIK产量为2.517mg/L,回补菌株ΔphlI/pBBR5pemIK-phlI的2,4-DAPG产量为354.348mg/L,过表达空载2P24/pBBR5pemIK的2,4-DAPG产量为16.069mg/L,过表达菌株2P24/pBBR5pemIK-phlI的2,4-DAPG产量为577.93mg/L。可以看出过表达菌株2P24/pbbR5pemIK::phlI的2,4-DAPG平均产量为577.93mg/L,较野生型荧光假单胞菌2P24的2,4-DAPG产量提高了5倍。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。
Claims (10)
1.一种phlI基因,其特征在于,所述phlI基因正调控2,4-DAPG合成,该基因具有如SEQID NO.1所示的核苷酸序列。
2.根据权利要求1所述的phlI基因,其特征在于:所述phlI基因位于2,4-DAPG基因簇上。
3.一种权利要求1-2任一所述的phlI基因在提高2,4-二乙酰基间苯三酚产量中的应用。
4.根据权利要求3所述的应用,其特征在于:所述phlI基因过表达或敲除后回补提高2,4-二乙酰基间苯三酚产量。
5.一种重组质粒,其特征在于,所述重组质粒中包含phlI启动子和如权利要求1-2任一所述的phlI基因。
6.根据权利要求5所述的一种重组质粒,其特征在于,所述重组质粒中插入片段具有如SEQ ID NO.3所示的核苷酸序列,所述如SEQ ID NO.3所示的核苷酸序列包含phlI启动子序列和所述phlI基因序列。
7.根据权利要求6所述的一种重组质粒,其特征在于,所述重组质粒为pBBR5pemIK质粒。
8.高产2,4-DAPG的遗传工程菌,其特征在于,所述遗传工程菌包含如权利要求5或7任一所述重组质粒,所述遗传工程菌为在敲除菌株ΔphlI中回补phlI基因或野生菌株2P24中过表达phlI基因制备获得。
9.根据权利要求8所述的遗传工程菌,其特征在于,所述遗传工程菌为荧光假单胞菌Pseudomonas fluorescensΔphlI或Pseudomonas fluorescens 2P24。
10.一种如权利要求8-9任一所述的遗传工程菌在提高2,4-二乙酰基间苯三酚产量中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311170521.7A CN117025639A (zh) | 2023-09-12 | 2023-09-12 | 一种phlI基因及其在提高2,4-二乙酰基间苯三酚产量中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311170521.7A CN117025639A (zh) | 2023-09-12 | 2023-09-12 | 一种phlI基因及其在提高2,4-二乙酰基间苯三酚产量中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117025639A true CN117025639A (zh) | 2023-11-10 |
Family
ID=88637510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311170521.7A Pending CN117025639A (zh) | 2023-09-12 | 2023-09-12 | 一种phlI基因及其在提高2,4-二乙酰基间苯三酚产量中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117025639A (zh) |
-
2023
- 2023-09-12 CN CN202311170521.7A patent/CN117025639A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gao et al. | Engineered fungal polyketide biosynthesis in Pichia pastoris: a potential excellent host for polyketide production | |
CN107709565B (zh) | 聚类异戊二烯、载体、转基因植物的制造方法,充气轮胎的制造方法及橡胶制品的制造方法 | |
CN110484572B (zh) | 一种提高酿酒酵母橙花叔醇产量的方法 | |
CN111019878B (zh) | L-苏氨酸产量提高的重组大肠杆菌及其构建方法与应用 | |
CN114381415B (zh) | 高产pha的基因重组菌及其构建方法 | |
KR20200026261A (ko) | 엑토인-생산 효모 | |
US11254709B2 (en) | Method for promoting Bacillus subtilis to synthesize surfactin based on multi-gene synergy | |
CN110651034A (zh) | 用于制备fdca的fdca-脱羧单加氧酶-缺陷的宿主细胞 | |
CN111117942B (zh) | 一种产林可霉素的基因工程菌及其构建方法和应用 | |
WO2016029802A1 (zh) | 虫草素的合成基因簇的鉴定和应用 | |
Wang et al. | Homologous overexpression of genes in Cordyceps militaris improves the production of polysaccharides | |
CN110590920B (zh) | 一种l-丝氨酸转运蛋白及其应用 | |
CN114196646B (zh) | 一种橄榄醇合成酶变体a及其用途 | |
CN113106114A (zh) | 调控里氏木霉蛋白表达效率的因子、调控方法及应用 | |
CN114317306A (zh) | 一种合成白藜芦醇的基因工程菌株及其构建方法与应用 | |
CN110656075A (zh) | 一种合成乙酰辅酶a衍生产品的通用性底盘细胞及其构建方法与应用 | |
CN116926092B (zh) | 一种泛酸激酶基因RkPank及其应用 | |
CN117025639A (zh) | 一种phlI基因及其在提高2,4-二乙酰基间苯三酚产量中的应用 | |
EP3371304A1 (en) | Drimenol synthases iii | |
CN112375725B (zh) | 一种生产维生素b6的代谢工程菌株及其构建方法与应用 | |
CN112779202B (zh) | 一种敲除基因proP和proVWX高产苏氨酸的工程菌及其应用 | |
CN114349830B (zh) | 一种PhlH蛋白突变体及其在提高2,4-二乙酰基间苯三酚产量中的应用 | |
CN108441508B (zh) | 地衣芽孢杆菌DW2ΔlrpC在杆菌肽生产中的应用 | |
CN112877349A (zh) | 一种重组表达载体、包含其的基因工程菌及其应用 | |
CN116121083B (zh) | 一种产卵孢素球孢白僵菌菌株及其在czb中合成卵孢素的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |